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Abstract
Histone acetylation is a key modification that regulates chromatin accessibility. Here we show that
treatment with butyrate or other histone deacetylase (HDAC) inhibitors does not induce histone
hyperacetylation in metaphase-arrested HeLa cells. When compared to similarly treated interphase
cells, acetylation levels are significantly decreased in all four core histones and at all individual sites
examined. However, the extent of the decrease varies, ranging from only slight reduction at H3K23
and H4K12 to no acetylation at H3K27 and barely detectable acetylation at H4K16. Our results show
that the bulk effect is not due to increased or butyrate-insensitive HDAC activity, though these factors
may play a role with some individual sites. We conclude that the lack of histone acetylation during
mitosis is primarily due to changes in histone acetyltransferases (HATs) or changes in chromatin.
The effects of protein phosphatase inhibitors on histone acetylation in cell lysates suggest that the
reduced ability of histones to become acetylated in mitotic cells depends on protein phosphorylation.
Keywords
Histone acetylation; mitosis; HDAC inhibitors; butyrate; metaphase chromosomes; protein
phosphatases
Introduction
Histones are the most abundant proteins associated with DNA in eukaryotic chromosomes.
The core histones H2A, H2B, H3 and H4 wind the DNA into bead-like nucleosome cores [1,
2], while histone H1 organizes the “string of beads” into a 30 nm chromatin fiber [3,4]. In
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addition to packaging the DNA and neutralizing some of its negative charge, the histones also
play roles in DNA replication, repair and transcription.
Histone function is modulated by several different post-translational modifications, one of
which is the reversible acetylation of lysine residues in the N-terminal tails of the four core
histones. Histone acetylation is a dynamic process involving a balance between histone
acetyltransferase (HAT) and histone deacetylase (HDAC) activities, and it is important because
it correlates with gene transcription or readiness for transcription [5-11].
Normally only a small percentage of core histone molecules is more than monoacetylated.
However, histone acetyl groups turn over rapidly [12]. In cultured cell lines, 70% of the acetate
incorporated into histones in a short pulse turns over with a half-life of about 3 min, and the
rest with a half-life of 30-40 min [12]. As a result, treatment of interphase cells for a few hours
with HDAC inhibitors such as sodium butyrate, valproic acid, trichostatin A (TSA), apicidin
or oxamflatin leads to significant histone hyperacetylation [13-20]. Evidence indicates that
butyrate and TSA are competitive inhibitors of HDACs [21-22], and based on structural
similarity to butyrate or acetyllysine, apicidin [23] and valproate probably are also. The mode
of inhibition by oxamflatin has not been reported.
Histone acetylation levels are lower during mitosis than during interphase in mammalian cells
[24-33] and in Physarum polycephalum [34,35]. Histone acetylation is also decreased during
the later stages of meiosis in Lilium microsporocytes [36] and in mouse oocytes [37]. The
reason for the decrease in histone acetylation at mitosis is not known. However, it could be
related to the cessation of transcription during mitosis in higher eukaryotes (e.g., [38-41]),
either as a cause or a consequence.
In the work reported here, we have explored the possible reasons for underacetylation of
histones at mitosis by treating metaphase-arrested HeLa cells with HDAC inhibitors. We find
that this treatment results in little or no increase in core histone acetylation. Since the effect is
seen in bulk chromatin, it is not due merely to the cessation of transcription. Our results suggest
that the causes may be complex, but that the phenomenon reflects reduced turnover of histone
acetates in mitotic cells and decreased ability of HATs to act on histones in mitotic chromatin.
In vitro experiments suggest that decreased histone acetylation at mitosis is dependent on
mitosis-specific protein phosphorylation of an as-yet unknown target.
Materials and Methods
Chemicals, Media and Antibodies
Microcystin LR was dissolved at 1 mM in 50 mM Tris-Cl pH 7.0 and stored in aliquots at −20°
C. Calyculin A was prepared as a 100 μM solution in methanol and stored at 2°C. Cantharidin
was prepared as a 200 mM solution in N,N-dimethylformamide (DMF) and stored at 2EC.
Sodium butyrate was made as a 5 M stock solution in 0.9% NaCl and 20 mM sodium phosphate
and adjusted to pH 7.4. Trichostatin A (TSA), oxamflatin and apicidin were prepared as 1 mg/
mL solutions in dimethylsulfoxide (DMSO) and stored at −20°C. Media and components were
obtained from Gibco or Sigma. All other reagents were obtained from Sigma unless otherwise
noted.
Some of the antibodies recognizing specific core histone acetylations were gifts from Dr.
Hiroshi Kimura (Osaka) or Dr. Maria Vogelauer (Edinburgh). Antisera from the Turner
laboratory were prepared and characterized as described by Turner and Fellows [29] and White
et al. [42]. The following were used (all rabbit polyclonal antibodies unless otherwise noted):
anti-H2AK5ac (Turner, R123); anti-H2BK12ac/K15ac (Turner, R209); anti-H3K9ac (Upstate,
07-352), anti-H3K18ac (Upstate, 07-354); anti-H3K23ac (Upstate, 07-355); anti-H3K27ac (H.
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Kimura, 309, mouse monoclonal [43]); anti-H4K8ac (Upstate, 07-328); anti-H4K8ac (Turner,
R403); anti-H4K12ac (Upstate, 07-595); anti-H4K12ac (Upstate, 06-761); anti-H4K16ac
(Turner, R251); and anti-pan-H4, loading control (Upstate, 05-858). Note that Upstate 07-354
has been found to react with both H3K18ac and H3K14ac (M. Vogelauer, personal
communication), and R209 requires either H2BK12 or H2BK15 to be acetylated, or both.
Cell Culture and Metaphase-Arrest
All biochemical experiments used suspension cultures of either H-HeLa [44] or HeLa S3. H-
HeLa cells were grown in Eagle's MEM as previously described [45]. HeLa S3 cells were
grown in RPMI-1640 supplemented with penicillin/streptomycin and 10% fetal bovine serum
and diluted daily to 2.0 – 2.5 H 105/mL. For metaphase arrest, cells were first synchronized
with thymidine [46] and then arrested with nocodazole as described previously [45]. Mitotic
indices were typically 80-95% for H-HeLa and 95-98% for HeLa S3. In no case were any
differences in results observed between the two strains.
Treatment with HDAC Inhibitors; Isolation of Mitotic Chromosomes and Interphase Nuclei
Cell cultures with 2 – 4 H 105 cells/mL were typically treated with 10 mM sodium butyrate,
1.0 Φg/mL trichostatin A, 2.0 Φg/mL apicidin, or 2.0 Φg/mL oxamflatin. For most
experiments, cells were placed on ice immediately at the end of the treatment period and
metaphase chromosome clusters were isolated as previously described [47,48]. Lysis Buffer
(LB) consisted of 10 mM Na+-Hepes, pH 7.4, 10 mM NaCl, 5 mM MgCl2, 0.5 M sucrose and
0.1% NP40, and Resuspension Buffer (RB) had the same composition but without sucrose.
The lysate was subjected to 6 strokes in a glass-glass Dounce homogenizer with a tight fitting
pestle (Wheaton Glass) and the chromosome clusters were pelleted through a layer consisting
of RB plus 1.2 M sucrose. Crude interphase nuclei were isolated similarly, except using 15 –
20 strokes of the Dounce homogenizer and omitting the 1.2 M sucrose layer. Lysis solutions
contained 2 mM p-chloromercuriphenyl sulfonate (PCMPS) or 2 mM p-
hydroxymercuribenzoate (PHMB) to block histone dephosphorylation [49] and 10 mM
butyrate or 1 μg/mL TSA to prevent histone deacetylation.
For the experiment shown in Fig. 5, cells were released from a thymidine block and after 4 hrs
both nocodazole and 10 mM butyrate were added. At 16 hrs after release from thymidine, cells
(mitotic index 60 – 70%) were harvested. Individual metaphase chromosomes were isolated
by the aqueous method of Marsden and Laemmli [50] and purified away from nuclei by
differential centrifugation. For comparison, nuclei were isolated from interphase
(unsynchronized) cells that had been treated with 10 mM butyrate for 12 hrs.
Light microscopy: Preparation of chromosome spreads and immunostaining
For immunofluorescence microscopy, metaphase chromosome spreads were prepared from
human female lymphoblastoid cells grown in RPMI 1640 medium plus 10% fetal bovine serum.
Cells in exponential growth were treated for 6 hrs with 1 mM sodium valproate, including the
final 2 hrs with 0.1 μg/mL colcemid (KaryoMax, Gibco). Cells were then pelleted by
centrifugation, washed twice with cold phosphate buffered saline (PBS), resuspended in 75mM
KCl at 2×105 cells/ml and left at room temperature for 10 min. 200μL aliquots of the swollen
cell suspension were spun onto glass slides at 1800 rpm for 10min in a Shandon Cytospin 4.
Slides were then immersed for 10 min at room temperature in KCM buffer (120mM KCl,
20mM NaCl, 10mM Tris/HCl pH 8.0, 0.5mM EDTA, 0.1% Triton X-100). Immunolabelling
was carried out for 1hr at 4°C as described previously [51] with antisera diluted 200-400 fold
in KCM supplemented with 1-1.5% BSA (Sigma). For all labelings, the secondary antibody
was FITC-conjugated goat anti-rabbit immunoglobulin (Sigma F1262) diluted 150-fold in
KCM, 1% BSA. Slides were washed twice in KCM (5 min at room temperature), fixed in 4%
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v/v formaldehyde (10 min at room temperature), rinsed in deionised water and mounted in
Vector Shield (Vector Lab) supplemented with DAPI (Sigma) at 2μg/ml.
Observation of HAT Activity in Lysates
HeLa cells were pelleted, washed twice with saline, and lysed at 1.0 H 107 cells/mL in HAT
buffer consisting of 50 mM Tris-Cl pH 8.0, 50 mM KCl, 0.1 mM EDTA, 5% glycerol, 1 mM
phenyl methyl sulfonylfluoride (PMSF; from a stock solution 0.5 M in 2-propanol), 10 mM
sodium butyrate, 1 mM dithiothreitol, 1 mM acetyl coenzyme A and 0.2% Nonidet P40. The
protein phosphatase inhibitor cantharidin [52] was used at a final concentration of 1 mM. DMF
was evaporated with a gentle stream of air and the cantharidin redissolved in the appropriate
volume of HAT buffer. Lysates were incubated for 2 hrs at 37°C with agitation to keep
chromosomes or nuclei in suspension. Chromosomes or nuclei were then pelleted and histones
extracted.
Histone Extraction, Polyacrylamide Gel Electrophoresis, and Detection
Histones were extracted from pelleted chromosomes or nuclei with 0.2 M H2SO4 as previously
described [49]. For SDS-polyacrylamide gels, sample preparation and electrophoresis were
carried out as described by Laemmli and Favre [53]. All gels contained 15% acrylamide and
0.4% N,N′-methylene-bis-acrylamide. For 3H-labelling experiments (e.g., Fig. 2), 16 cm long
gels were used. For immunoblotting experiments (e.g., Fig. 3), 6 cm long mini-gels were used.
For acid-urea gel electrophoresis [54], samples of acid-extracted histones were dried in 1.5 mL
microcentrifuge tubes using a CentriVap (Labconco) and redissolved in 3 – 6 μL of sample
buffer for loading. 16 cm long gels containing 15% acrylamide, 0.1% N,N′-methylene-bis-
acrylamide, 2.5 M urea and 5.4% acetic acid were pre-run as described in [55] and then run at
300 V for 5 – 6 hrs until the blue component of the methyl green marker reached the bottom
of the gel.
Gels were stained with 0.1% Coomassie Brilliant Blue R250 (BioRad) in 50% methanol, 10%
acetic acid and destained in 5% methanol, 10% acetic acid. For detection of 3H-labelled
proteins, Coomassie-stained gels were soaked in water to remove methanol and acetic acid,
soaked in Fluoro-Hance (Research Products International) for at least 30 min, and finally dried
on Whatman 3MM CHR filter paper (which was first wetted in Fluoro-Hance) in a vacuum
gel drier. Autofluorography was carried out using Fuji RX Medical X-ray film that had been
sensitized by pre-exposure to an even, low-intensity flash of light [56].
For immunoblotting, proteins were electrophoretically transferred to Hybond ECL
nitrocellulose membranes (Amersham Biosciences) in a BioRad Miniprotean apparatus.
Membranes were blocked with 5% milk in phosphate-buffered saline (PBS), incubated with
the primary antibody (typically 1:500 to 1:1000) in 5% milk in PBS, washed 3 times in PBS,
and incubated with the appropriate HRP-conjugated secondary antibody in 3% milk in PBS.
Bands were detected by chemiluminescence (ECL, GE Health Sciences).
[3H]-Acetate Labeling of Histones In Vivo
The procedure was modified from that of Cousens et al. [16]. For a given experiment, to insure
that the concentrations of metaphase and interphase chromatin were equal [57], cells from 50
mL of each culture were pelleted, washed twice with cold 0.9% NaCl and lysed in 10 mL RB.
A 100 ΦL aliquot of this lysate was diluted to 5 mL with 1% aqueous SDS, mixed well and its
absorbance measured at 260 and 280 nm. Based on these measurements, metaphase-arrested
and interphase cultures were adjusted to the same concentration of chromatin before adding
[3H]-acetate.
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The total amount of [3H]-acetate (DuPont NEN, 25 mCi/mL in ethanol) to be used in an
experiment was placed in a single flask, the solvent evaporated with a gentle stream of air, and
the [3H]-acetate redissolved in warm medium. Metaphase and interphase cultures were then
treated at the same time with the same amount of [3H]-acetate and incubated identically at
37EC with magnetic stirring. Incorporation was stopped by adding two volumes of ice cold
0.9% NaCl and placing the cultures on ice for 15 min. Cells were washed twice in cold 0.9%
NaCl, nuclei or chromosome clusters were isolated, and finally histones were extracted with
0.2 M H2SO4.
Lysate supernatants were saved and used to compare the relative specific activity of acetyl
coenzyme A in the metaphase and interphase cells by HPLC using a modification of the method
of Hosokawa et al. [58]. Samples were centrifuged at 14,000 rpm for 2 min in a microcentrifuge
to remove large particulates. Next, HCl was added to a final concentration of 0.2 N and the
samples again centrifuged. The remaining samples were dried using a CentriVap, redissolved
in 0.2 M ammonium acetate, and fractionated using a Shimadzu LC-10AS HPLC with
SPD-10A UV-Visible detector, a 25 cm C-18 column (Alltech) and a flow rate of 1 mL/min.
During the first 10 min, the solvent consisted of 2% acetonitrile and 98% 0.2 M ammonium
acetate. During the next 15 min, the acetonitrile concentration rose linearly to 30%. Fractions
were collected and 3H determined by scintillation counting. Acetyl coenzyme A (Sigma) and
[3H]-acetyl coenzyme A (DuPont NEN) eluted at 20.5 min.
Histone Deacetylase Assay
The assay was modified from [16]. Substrate histones were labeled in vivo with [3H]-acetate
and extracted with 0.2 M H2SO4 as described above, redissolved in 1 mM HCl, dried in aliquots
using the CentriVap, and stored at !20EC. Fluorography of SDS gels showed that core histones
were the only 3H-labeled proteins present.
For the assay, labeled histones (containing approximately 1000 cpm/Φg) were dissolved at 1
mg/mL in RB, and interphase and metaphase cells were lysed at equivalent concentrations (see
above) in LB. For the reaction, prewarmed substrate histone solution (20 ΦL) and crude cell
lysate (20 ΦL) were mixed and incubated at 37EC. The reaction was stopped by adding 20
ΦL carrier histones (calf thymus histone type II-AS, Sigma, dissolved at 1 mg/mL in 0.1 M
acetic acid and 0.4 N HCl) and 40 ΦL of a saturated solution of Reinicke salt (ammonium
tetrathiocyanodiammonochromate). Samples were mixed well, placed on ice for at least 30
min and then centrifuged for 5 min at full speed in a microcentrifuge to pellet the 3H-labeled
histones. The [3H]-acetate released by deacetylase action was determined in 75 ΦL of the
supernatant by scintillation counting.
Typically the amount of [3H]-acetate released was followed as a function of time. As a control,
a baseline was determined with LB in place of lysate (i.e., with no deacetylase present), and
in this case every time point contained less than 100 cpm. With lysate, the amount of [3H]-
acetate released (above the 100 cpm background) was linear from 0 to 9 mins of incubation
(Fig. 7A). For a given time point, the amount of 3H released was proportional to the lysate
concentration up to 2 H 107 cells/mL (Fig. 7B).
Results
HDAC Inhibitors do not induce hyperacetylation of histone H4 in metaphase-arrested HeLa
cells
Treatment of interphase mammalian cells with histone deacetylase (HDAC) inhibitors is
known to induce hyperacetylation of core histones (e.g., [13-19]). In order to determine whether
the same is true of mitotic cells, HeLa cultures were synchronized in S-phase by treatment with
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2.5 mM thymidine for 20-24 hrs, released from the thymidine block, and treated 4 hrs later
with 0.25 μg/mL nocodazole to arrest in metaphase [45,46]. At 16 hrs after release from
thymidine, the metaphase-arrested cells were treated with 10 mM sodium butyrate. For
comparison, interphase (unsynchronized) cultures were treated in parallel. At various times
after treatment, samples were immediately placed on ice and chromosomes or nuclei were
isolated [47,48]. Histones were extracted with acid and H4 acetylation was analyzed by acid
urea gel electrophoresis. This method separates proteins partly on the basis of charge and is
able to resolve histone H4 species containing zero, one, two, three or four acetylated residues
(e.g., [13-15]).
The results of one such experiment are shown in Fig. 1A and B. With interphase cells (Fig.
1B), histone H4 becomes highly acetylated after only 1 hr. By contrast, metaphase-arrested
cells (Fig. 1A) show little or no increase in H4 acetylation even after 5 hrs of treatment Note
that in Fig. 1A, histone H1 is almost entirely in the highly phosphorylated (and lower mobility)
form characteristic of mitosis (H1M). This confirms that the culture was arrested to a high
mitotic index.
Other HDAC inhibitors give essentially the same results as butyrate. The acid-urea gel shown
in Fig. 1C and D compares histones of metaphase-arrested cells and interphase cells that have
been incubated for 4 hrs with 1.0 μg/mL Trichostatin A (lanes 1), 2.0 μg/mL apicidin (lanes
2), 2.0 μg/mL oxamflatin (lanes 3), or 10 mM sodium butyrate (lanes 4), or without any HDAC
inhibitor (Ctrl). With interphase cells (Fig. 1D), comparison with the control (Ctrl) shows that
in all cases histone H4 becomes hyperacetylated. In metaphase-arrested cells (Fig. 1C) on the
other hand, there is little or no increase in histone H4 acetylation with any of the four HDAC
inhibitors. Note again in Fig. 1C that histone H1 is mainly in its mitotic, highly phosphorylated
form (H1M).
Lack of hyperacetylation after treatment of metaphase-arrested cells with butyrate is also
observed with histones H2A, H2B and H3
The results shown in Fig. 1 demonstrate that treatment with HDAC inhibitors leads to
hyperacetylation of histone H4 in interphase HeLa cells but not in metaphase-arrested cells.
To test whether the same is true of H2A, H2B and H3, metaphase-arrested and interphase
cultures were treated simultaneously with sodium butyrate and [3H]-acetate for 1 hour.
Separate portions of the same cultures were incubated with [3H]-acetate in the same way but
without butyrate. Histones were then extracted and separated by SDS-polyacrylamide gel
electrophoresis. Total protein was visualized by Coomassie blue staining (Fig. 2A) and [3H]-
acetate-labeled proteins were observed by autofluorography (Fig. 2B).
It is clear from Fig. 2B that much less [3H]-acetate is incorporated into histones in metaphase-
arrested cells than in interphase cells. In interphase cells in the absence of butyrate (lane 1),
labeling of histone H2A is detectable and labeling of H3 and H4 is quite strong. In the presence
of butyrate, even more [3H]-acetate is incorporated into histones H2A, H3 and H4 in interphase
cells (lane 2). In metaphase-arrested cells, on the other hand, labeling of histones is only barely
detectable in the absence of butyrate (lane 3) and it is only slightly increased in the presence
of butyrate (lane 4). (The small amount of labeling of H3 and H4 seen in Fig. 2B lanes 3 and
4 may be due in part to interphase contamination.) Note that histone H2B is not resolved from
H3 on this gel, so we cannot say whether or not it is acetylated in interphase cells based on this
data. However, H2B has been reported to become highly acetylated in butyrate-treated
interphase HeLa cells [59,25] and it is clearly not acetylated in butyrate-treated metaphase-
arrested cells (Fig. 2B, lane 4). Lack of H2B acetylation at K12 and K15 in butyrate-treated
metaphase cells is confirmed in Fig. 3 (see below).
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These results are not due to differences in the amount of protein loaded or differences in the
efficiency of [3H]-acetate incorporation into cellular acetyl coenzyme A pools. Coomassie blue
staining demonstrates that the four samples contained equivalent amounts of each histone (Fig.
2A). Analysis of cell lysate supernatants by HPLC revealed essentially the same amount
of 3H-label in acetyl coenzyme A in metaphase-arrested cells and interphase cells (data not
shown).
We conclude from the results in Figs. 1 and 2 that when metaphase-arrested cells are treated
with butyrate none of the core histones become highly acetylated.
Butyrate treatment of metaphase-arrested cells fails to induce hyperacetylation at several
specific acetylation sites in the core histones
We next asked whether the lack of histone acetylation following butyrate treatment of
metaphase-arrested cells is a characteristic of all acetylation sites, or only some of them.
Histone extracts were prepared from four HeLa cell cultures: (1) interphase cells
(unsynchronized); (2) interphase cells as in (1) but treated 4 hrs with 10 mM butyrate; (3)
metaphase-arrested cells (mitotic index 97%); and (4) metaphase arrested cells as in (3) but
treated 4 hrs with 10 mM butyrate. The histones were separated on SDS-polyacrylamide gels
and acetylation was detected by immunoblotting using antibodies recognizing specific
acetylated lysine residues. Antibody recognizing bulk histone H4 was used as a loading control
(bottom panel).
The results of this analysis are shown in the first four lanes of Fig. 3. Nine different anti-
acetylhistone antibodies were used, and in all cases the level of acetylation is clearly decreased
in butyrate-treated mitotic cells (lane 4) compared to butyrate-treated interphase cells (lane 2).
However, it is also clear that the extent of the decrease differs for the various acetylation sites.
For example, butyrate-treated mitotic cells show significant amounts of acetylation at H4K12
and H3K23, though still much less than in the butyrate-treated interphase cells. On the other
hand, little or no acetylation is detected in butyrate-treated mitotic cells with anti-H2BK12ac/
K15ac, anti-H4K16ac or anti-H3K27ac antibodies (Fig. 3, lane 4).
The lack of detectable H2BK12ac/K15ac and H3K27ac in butyrate-treated metaphase-arrested
cells, together with the strong signals at those sites in butyrate-treated interphase cells, suggests
that the metaphase-arrested culture was not detectably contaminated with interphase cells. It
follows that the small amount of acetylation seen in butyrate-treated metaphase-arrested cells
at H3K9, H3K14/K18, H3K23, H4K8 and H4K12 (Fig. 3, lane 4) cannot simply be attributed
to interphase contamination. This is significant because the amount of acetylation at H3K9,
H3K14/K18, H3K23, H4K8 and H4K12 is clearly greater in butyrate-treated metaphase cells
than in untreated metaphase cells (compare Fig. 3, lanes 3 and 4). Since the increased
acetylation at these sites is not due to interphase contamination, we conclude that some small
amount of acetylation must be occurring at these sites in metaphase-arrested cells, though of
course much less than in interphase cells. Thus, not all HATs are completely inhibited or
blocked from acetylating histones in mitotic cells.
Immunofluorescence microscopy detects no change in distribution of acetylated H4 across
metaphase chromosomes following HDAC inhibitor treatment
The biochemical analyses of bulk histones in Figs. 1 – 3 cannot detect changes in the
distribution or level of histone acetylation that are limited to particular chromosome regions
or that affect only specific chromatin types. To determine whether large scale regional changes
occur following treatment with HDAC inhibitors, we used immunofluorescence microscopy
to study the distribution of acetylated H4 across metaphase chromosomes. Human female
lymphoblastoid cells were used because they are diploid, have an inactive X chromosome (an
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example of facultative heterochromatin) which is substantially underacetylated relative to other
chromosomes, and provide metaphase chromosome spreads suitable for immunolabelling and
karyotypic analysis. Cells were treated with the HDAC inhibitor valproic acid (VPA, [20]), a
short chain fatty acid equivalent to butyrate but better tolerated by these cells. As shown in
Figure 4, exposure to VPA for 6h caused no measurable increase in H4 acetylation along the
chromosome arms, nor did it change the underacetylation of the constitutive heterochromatin
at centromeres (arrowheads) or the facultative heterochromatin of the inactive X chromosome
(arrows). Although we cannot eliminate the possibility of subtle changes below the level of
resolution of the light microscope, it seems that VPA causes no detectable overall changes in
either the level or chromosomal distribution of H4 acetylation.
Decreased ability of H3 and H4 to become acetylated following treatment with butyrate is not
due to butyrate-insensitive HDAC activity
The results presented in Figs. 1 – 3 could conceivably be explained by the presence of butyrate-
insensitive HDACs or by increased HDAC activity during mitosis. In these scenarios, lack of
histone hyperacetylation in metaphase-arrested cells would be due to significant residual
HDAC activity, even in the presence of the usual HDAC inhibitors.
To test the hypothesis that butyrate-insensitive HDACs are present during mitosis,
synchronized HeLa cells were treated with 10 mM sodium butyrate for 12 hours starting in
mid-S-phase and continuing through G2-phase and into metaphase-arrest. With this procedure,
mitotic indices of only 60 – 70% are obtained. Therefore, to minimize interphase
contamination, individual mitotic chromosomes were isolated before extracting histones.
The hypothesis predicts that such chromosomes should not contain hyperacetylated histones,
because any acetyl groups added during S- or G2-phase would be removed by butyrate-
insensitive deacetylases after the cells were arrested in mitosis. Contrary to this prediction,
histone H4 was found to be highly acetylated in these mitotic chromosomes (Fig. 5, lanes 4
and 5). Controls in Fig. 5 include histones from interphase cells treated with butyrate (lane 1),
untreated interphase cells (lane 2), and untreated mitotic cells (lane 3). The relative amounts
of multiply acetylated H4 species appear to be slightly less in lanes 4 and 5 than in lane 1,
perhaps because the histones had less time to become acetylated (i.e., only until the cells entered
mitosis).
The presence of some H1I (the unphosphorylated interphase form of histone H1) in Fig. 5,
lanes 4 and 5 raises the possibility of interphase contamination. However, the amount of H1I
is relatively minor, suggesting that there is too little interphase contamination to account for
the extensive acetylation of H4 seen in these samples. To test this possibility further, histones
from metaphase-arrested cells that were not treated with butyrate (Fig. 5, lane 3) were mixed
with histones from butyrate-treated interphase cells (Fig. 5, lane 1) in proportions to mimic the
amount of H1I seen in Fig. 5, lanes 4 and 5. In such a sample, acetylated H4 is not detectable
on acid-urea gels (Fig. 5, lane 6).
To further test the hypothesis that butyrate-insensitive HDACs exist in mitotic cells, samples
like those in Fig. 5 lanes 4 and 5 were analyzed by immunoblotting using antibodies specific
for various acetylation sites in core histones. The results (Fig. 3, lane 5) show significant
acetylation at all sites in H3 and H4. On the other hand, there appears to be little or no acetylation
of H2AK5 or H2BK12/K15 in this sample. Evidently those sites were either (a) acetylated
when the cells entered metaphase arrest, but then deacetylated, or (b) not acetylated at the time
the cells entered metaphase arrest. The first possibility would suggest that during mitosis
HDACs specific for those sites are present that either have a high level of activity or are
insensitive to butyrate. The second possibility, which seems more likely, would suggest that
those sites are not acetylated during G2-phase.
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To summarize, hyperacetylated histones are indeed found in mitotic chromosomes when the
cells have been treated with butyrate during late S- and G2-phase. We conclude that, at least
in the case of histones H3 and H4, the lack of acetylation in metaphase-arrested cells treated
with HDAC inhibitors (Figs. 1 – 3) cannot be attributed to butyrate-insensitive HDACs active
during mitosis.
Inability of histones to become hyperacetylated in metaphase-arrested cells is related to
mitotic protein phosphorylation
As a first step toward eventually testing whether HATs are down-regulated during mitosis or
acetylation sites are inaccessible in mitotic chromosomes, we used a simple in vitro system in
which cells are lysed in the presence of acetyl coenzyme A and butyrate in a buffer favorable
for HAT activity. After incubation for 2 hrs at 37°C, histones are extracted and analyzed on
acid-urea gels (Fig. 6).
Following this procedure, hyperacetylation of histone H4 is seen both in lysates of interphase
cells (Fig. 6, lane 1) and in lysates of metaphase-arrested cells (Fig. 6, lane 2). However, when
cantharidin, an inhibitor of Protein Phosphatases (PPases) 1 and 2A [52], is included during
lysis of the metaphase-arrested cells, histone H4 does not become acetylated (Fig. 6, lane 3;
note the accumulation of non-acetylated H4, the lowest band). This suggests that the inability
of histone H4 to become acetylated following treatment of metaphase-arrested cells with
butyrate depends on phosphoproteins in the mitotic cells that become dephosphorylated
following cell lysis. It is well known that histone H1, histone H3 and other proteins are
dephosphorylated following lysis of metaphase-arrested cells [60,49], most likely by Protein
Phosphatase 1[48]. H1 dephosphorylation (shift from the H1M to H1I position) is clearly seen
in Fig. 6, lane 2, but cantharidin has prevented it in lane 3. Note that this does not necessarily
imply that the lack of histone H4 acetylation is due to H1 phosphorylation, but that remains
one possibility.
This result is not due to fortuitous inhibition of HATs by cantharidin, because histone H4 gets
highly acetylated in lysates of interphase cells whether or not cantharidin is present (Fig. 6,
lanes 4 and 5). We conclude that the repression of histone acetylation during mitosis depends
on phosphorylation of as-yet-unidentified proteins that are dephosphorylated following cell
lysis, but whose dephosphorylation is prevented by cantharidin.
Lack of histone acetylation in mitosis is not due to increased HDAC activity in metaphase-
arrested cells
As discussed above, the results in Figs. 3 and 5 show (at least for histones H3 and H4) that
butyrate-insensitive histone deacetylases are not present in metaphase-arrested HeLa cells at
significant levels. The same results also suggest that decreased histone acetylation during
butyrate treatment of these cells is not simply due to elevated (but still butyrate-sensitive)
HDAC activity. We have tested this second possibility further by comparing HDAC activity
in lysates. Lysates of interphase and mitotic cells were prepared so as to give equivalent
concentrations of chromatin (see Materials and Methods). Relative deacetylase activity was
determined as the amount of 3H released at various time points, using as a substrate exogenous
acid-extracted histones that had been labeled in vivo with [3H]-acetate. Note that for a given
lysate concentration, the amount of [3H]-acetate released is linear with respect to time (Fig.
7A) and for a given time point it is linear with respect to lysate concentration (Fig. 7B).
Fig. 7C and D indicate that HDAC activity is the same in metaphase-arrested and interphase
cell lysates. However, as shown in the previous section and Fig. 6, if differences in interphase
and mitotic HDAC activity existed in vivo, they would likely be due to mitosis-specific protein
phosphorylation. Such differences could be erased in vitro as a result of protein
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dephosphorylation following cell lysis. To examine this possibility, histone deacetylase
activity was assayed in lysates of metaphase-arrested and interphase cells prepared in the
presence of calyculin A and microcystin LR. These compounds, like cantharidin, are inhibitors
of Protein Phosphatases 1 and 2A [61, 62].
The results of this experiment are shown in Fig. 7E and F. Curiously, HDAC activity in
interphase lysates is slightly lower in the presence of phosphatase inhibitors, suggesting that
HDACs may be downregulated by phosphorylation during interphase (Fig. 7E). Nevertheless,
it is clear that in mitotic lysates, the rate of deacetylation is unaffected by the presence of
calyculin A or microcystin LR (Fig. 7F), contrary to what one would expect if HDACs were
upregulated by phosphorylation during mitosis. From this result and the results in Fig. 6 we
conclude that the phenomenon we observe is not primarily due to increased HDAC activity.
Discussion
Decreased acetylation of histones at mitosis in response to HDAC inhibitors
We have shown that the ability of histones to become acetylated following treatment of HeLa
cells with HDAC inhibitors is significantly diminished during mitosis. Multiacetylated histone
H4 isoforms are induced in interphase cells, but not in metaphase-arrested cells, by exposure
to sodium butyrate [13], trichostatin A [17], apicidin [18] or oxamflatin [19]. The effect is seen
with all four core histones and to varying degrees at all individual acetylation sites that have
been examined. Our results suggest further that this phenomenon depends on mitosis-specific
protein phosphorylation. Histone hyperacetylation occurs in lysates of metaphase-arrested cells
when histones and other proteins are allowed to become dephosphorylated by endogenous
phosphatases, but it does not occur when protein dephosphorylation is blocked by inhibitors
of Protein Phosphatases 1 and 2A [48].
Transcription, histone acetylation and mitosis
Histone acetylation is closely connected with gene transcription [63-66] and transcription is
shut off during mitosis (with some exceptions; e.g., [67]). The decreased ability of histones to
become acetylated during mitosis is probably not a result of switching off transcription because
it occurs in the bulk of the chromatin, not just in the small portion that was transcriptionally
active during the previous interphase. However, decreased histone acetylation could be part of
the cause of the cessation of transcription at mitosis.
The shut-off of transcription by all three RNA polymerases at mitosis involves phosphorylation
of basal transcription factors by Cdk1/cyclin B [68-71]. This may provide the full explanation,
particularly in the case of RNA Pol I [71]. However, there may be other mechanisms as well
[72,73] and the repression of core histone acetylation could be one of them. A striking feature
of our data is that in butyrate-treated metaphase-arrested cells, acetylation at H4K16 is only
barely detectable. H4K16 acetylation is essential for decompacting 30 nm fibers and
maintaining a structure that permits DNA transcription [74,4].
Possible explanations for the decreased ability of histones to become acetylated during
mitosis
Since histone acetylation involves a balance between HDACs and HATs, two general
hypotheses could explain the effect we have observed: (1) HDAC activity could be increased
during mitosis, and/or become insensitive to HDAC inhibitors; and (2) the ability of HATs to
acetylate histones in chromatin could be decreased during mitosis, either as a result of changes
to the HATs themselves or changes in the chromatin substrate.
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Based on our experiments, hypothesis (1) can be eliminated for most acetylation sites. Bulk
HDAC activity is not substantially different in interphase and metaphase lysates and is equally
sensitive to butyrate. In addition, mitotic chromosomes containing highly acetylated histones
can be isolated by treating cells with butyrate during late S- and G2-phase. The latter result
rules out the presence of butyrate-insensitive HDACs during mitosis, since histone acetyl
groups added during S- or G2-phase would be removed by such HDACs when the cells reached
metaphase arrest. Note that the isolation of individual mitotic chromosomes in this experiment
confirms the observation [75] that histone hyperacetylation does not completely block mitotic
chromosome condensation. However, hyperacetylation does lead to chromatin bridges and the
failure of chromatid segregation at anaphase [75]. This phenotype is similar to what is seen in
the absence of condensin [76], suggesting that histone deacetylation may be important for
stabilizing condensed mitotic chromosomes.
This leaves hypothesis (2) which states that HATs are less able to acetylate histones during
mitosis, either due to changes in the HATs themselves or changes in the chromatin substrate.
This could be the result of down-regulation of HAT activity, displacement of HATs from
chromosomes, changes in chromatin structure that make acetylation sites inaccessible to HATs,
or a combination of these mechanisms. Note that the same mechanisms need not be operative
for all HATs or for all sites.
Factors that could influence HAT activity through mitosis
In principle HAT activity could be down-regulated during mitosis by phosphorylation of HATs
themselves or associated proteins. This seems unlikely to be the primary mechanism, however.
Modulation of HAT activity by phosphorylation has been reported (e.g., [77-84]), but only
Tip60 is known to be phosphorylated specifically at mitosis, and in this case the modification
is stimulatory [85]. Kruhlak et al. [31] reported that HATs remain enzymatically active during
mitosis, but they only assayed total HAT activity so it is still possible that some HATs may be
down-regulated. One possible candidate for such a mode of control is hMOF, which is
responsible for H4K16 acetylation [86-88]. Our results show that H4K16 acetylation is only
barely detectable when metaphase-arrested cells are treated with butyrate, so perhaps hMOF
is switched off.
Alternatively, decreased HAT activity on histones during mitosis could be due to displacement
of HATs from the chromosomes, as proposed by Kruhlak et al. [31]. Failure of HATs to bind
to mitotic chromosomes could be a consequence of changes in chromatin structure or a result
of modification (e.g., phosphorylation) of the HATs themselves.
A final possibility is that histone acetylation sites could become inaccessible to HATs during
mitosis due to structural changes in the chromatin. Gross chromosome condensation probably
does not play a major role since condensed mitotic chromatin is known to be accessible to
transcription factors and other proteins in vivo [89]. However, inaccessibility of acetylation
sites could result from stabilization of 30 nm fibers or new interactions within the chromatin
fiber. Histone phosphorylation could be involved by altering contacts between different
nucleosomes or between histones and DNA.
One attractive hypothesis is that specific unacetylated lysine residues in the core histone tails
may interact electrostatically with phosphate groups in histones H1 and H3 during mitosis,
thereby stabilizing 30 nm chromatin fibers or condensed chromosomes. Alternatively, 30 nm
chromatin fibers may be stabilized during mitosis by interaction between unacetylated H4K16
and an “acidic patch” on a neighboring nucleosome [66,4]. In either case, accessibility of the
relevant lysine residues would normally be restricted during mitosis. Furthermore, extensive
acetylation of those sites would tend to disrupt the interactions and destabilize the condensed
chromosomes, as observed by Cimini et al. [75].
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Control of acetylation at specific lysine residues
In mammalian cells, acetylation of lysines in the N-terminal tails of histones H3 and H4
progresses in a non-random order from the mono-acetylated to the tetra-acetylated isoforms.
For example, in mono-acetylated H4, K16 is the predominant acetylated residue. K16, K8 and
K12 are acetylated in the di- and tri-acetylated isoforms while K5 is used only in the most
highly acetylated isoforms [90,59]. A similar situation occurs for H3 with K14 being acetylated
first, followed by K23, K18 and K9 [90,59]. Work on H4 acetylation in Tetrahymena [91] and
cuttlefish [92] has led to similar conclusions.
In bulk histones from untreated cells, the non-acetylated and mono-acetylated isoforms
predominate, with the more highly acetylated forms being rare. However, treatment with
HDAC inhibitors leads to rapid hyperacetylation and accumulation of more highly acetylated
isoforms, showing that there is rapid and continuing acetate turnover at all lysines.
It is likely that multiple HATs and HDACs are involved in setting the level of acetylation at
each site. The enzymes involved may also vary, either from one region of the genome to another
or throughout the cell cycle. Recent work on the properties of candidate enzymes is beginning
to provide clues about how lysine-specific acetylation might be regulated. In general, HATs
show more specificity than HDACs, which tend to show only limited preference for particular
lysines or histones [93-96]. For example, the acetyltransferase MOF shows a strong preference
for H4K16. Cells in which MOF is knocked down are depleted of acetylated H4, suggesting
that MOF has a dominant role in controlling bulk H4 acetylation [97]. However, the specificity
of HATs also depends on both the chromatin context in which they operate and on the proteins
that associate with them [98]. Thus, the HAT Rtt109 acetylates H3K14 and H3K23 in the
presence of the histone chaperone protein Vps75 but acetylates H3K56 in the presence of the
chaperone Asf1 [95,99,100].
We have shown here that turnover of H3 and H4 acetates is reduced (that is, the ability to
generate hyperacetylated isoforms in the presence of HDAC inhibitors is diminished) in
metaphase. We have also shown that the relative levels of acetylation of individual lysines are
altered in metaphase cells. Our results are consistent with previous work showing that H4K5
and H4K12 are more frequently acetylated in the mono-acetylated isoform in metaphase than
in interphase HeLa cells [29]. Altered patterns of lysine acetylation may be a consequence of
differences in turnover. For example, we show here that relative to other sites, H3K23ac is
much more commonly acetylated in metaphase than in interphase. During interphase, H3K23
is normally acetylated only in the di-, tri- and tetra-acetylated isoforms, but in butyrate-treated
cells it predominates in the mono-acetylated isoform [59]. It may be that more rapid acetate
turnover at H3K23 causes it to become the dominant site of acetylation after butyrate inhibition
of HDAC activity. In the absence of HDAC inhibitors, a reduction in HDAC activity as cells
progress into metaphase could exert the same effect. Reduced activity could be due to depletion
or modification of the enzymes, but it could also be simply due to their dissociation from
chromatin, in which case decreased HDAC activity would not be detected in assays of whole
cell extracts.
In summary, it is likely that progression from non-acetylated to hyperacetylated histones
requires the concerted action of multiple HATs, with a variety of site specificities, moderated
by less specific HDACs. If the activity levels of individual enzymes (or their locations on
chromatin) change as cells enter mitosis, then this will be reflected in changes in both the ability
to generate highly acetylated histone isoforms and the extent to which individual sites are
acetylated. While acetylation at individual sites would continue, albeit in a restricted way,
progression to more highly acetylated forms would not, largely because the depleted, or
relocated, HATs would rarely act on the same histone tail. Overall, this decrease in more highly
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acetylated forms of the core histones may then help to stabilize the characteristic condensed
structure of mitotic chromosomes.
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Fig. 1.
Lack of hyperacetylation of histone H4 following treatment of metaphase-arrested HeLa cells
with HDAC inhibitors. (A), (B) Time course of treatment of (A) metaphase-arrested and (B)
interphase (unsynchronized) HeLa cell cultures with 10 mM sodium butyrate. Histones were
extracted from isolated chromosomes or nuclei at the indicated times after treatment, separated
by acid-urea polyacrylamide gel electrophoresis [54] and stained with Coomassie blue. Note
that H4 is highly acetylated in interphase cells after one or more hours with butyrate, but no
increase in H4 acetylation is seen in metaphase-arrested cells even after five hours of treatment.
(C), (D) Effects of other HDAC inhibitors on histone H4 acetylation. Aliquots of (C)
metaphase-arrested and (D) interphase (unsynchronized) cultures were treated in parallel for
Patzlaff et al. Page 18
Exp Cell Res. Author manuscript; available in PMC 2011 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4 hrs with 1.0 Φg/mL trichostatin A (lanes 1), 2.0 Φg/mL apicidin (lanes 2), 2.0 Φg/mL
oxamflatin (lanes 3), or 10 mM sodium butyrate (lanes 4), or incubated for 4 hrs with no
treatment (Ctrl). Histones were extracted and analyzed as in (A) and (B). All four inhibitors
induce extensive acetylation of histone H4 in interphase but not in metaphase-arrested cells.
The positions of histone H4 and its acetylated forms, as well as mitotic (phosphorylated) and
interphase histone H1 (H1M and H1I, respectively) are indicated at the right. The abundances
of H1M and H1I verify that the cells were indeed predominantly mitotic in (A) and (C) and
interphase in (B) and (D). Only the portions of the gels containing the histones are shown.
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Fig. 2.
Sodium butyrate does not induce hyperacetylation of any of the four core histones in
metaphase-arrested HeLa cells. Interphase and metaphase-arrested cultures were grown under
identical conditions in the presence of [3H]-acetate for 1 hr, with or without the addition of 10
mM sodium butyrate. Histones were extracted and separated by SDS-polyacrylamide gel
electrophoresis; (A) Coomassie blue stain; (B) autofluorography to detect incorporated [3H]-
acetate. Only the portion of the gel containing the core histones is shown. Note that although
H3 and H2B are not resolved from one another on this gel, it is clear that neither of them is
highly labeled in metaphase cells, even in the presence of butyrate. Incorporation of [3H]-
acetate into acetyl coenzyme A pools was comparable in all cultures.
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Fig. 3.
Levels of acetylation at specific sites in core histones from mitotic and interphase cells, with
and without butyrate treatment. Histones were separated on SDS-polyacrylamide gels and
acetylation was detected by immunoblotting with specific anti-acetylhistone antibodies. Gels
run with the same samples and the same loadings and stained with Coomassie blue or probed
with anti-pan histone H4 as a loading control indicated that the five samples contained
essentially the same amounts of each of the four core histones. For the samples in lanes 1-4,
cultures were treated for 4 hrs with or without 10 mM sodium butyrate and histones were
extracted from isolated chromosome clusters or nuclei: lane 1, interphase, untreated; lane 2,
interphase, treated with butyrate; lane 3, metaphase-arrested, untreated; lane 4, metaphase-
arrested, treated with butyrate. The metaphase-arrested culture (lanes 3 and 4) had a mitotic
index of 97% and showed no detectable interphase histone H1 (H1I) on acid-urea gels. For the
sample in lane 5, a culture synchronized in mid-S-phase was treated with 10 mM butyrate for
12 hrs until most of the cells had arrested in metaphase. Individual chromosomes were then
isolated and histones extracted. On an acid-urea gel, the interphase form of histone H1 (H1I)
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was undetectable, demonstrating that this sample was free of contamination by interphase
histones.
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Fig. 4.
Immunolabeling of acetylated histone H4 on human metaphase chromosomes with or without
treatment with the HDAC inhibitor valproic acid (VPA).
Chromosome spreads from human female lymphoblastoid cells were immunolabeled with
antibodies to H4K8ac (green) and counterstained with DAPI (pseudocolored red). VPA-treated
cells were exposed to 1 mM sodium valproate for 6 hrs, including 2 hrs in colcemid prior to
harvesting and chromosome preparation. This treatment induces hyperacetylation of bulk
histones comparable to that shown in Fig.1B (E. Terrenoire and B.M. Turner, unpublished
results). Untreated cells were exposed to colcemid only. The inactive X chromosome (white
arrow) is essentially unlabeled in both treated and untreated cells, as are blocks of centric
heterochromatin (white arrowheads).
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Fig. 5.
Treatment of synchronized cells with butyrate during entry into metaphase-arrest allows
isolation of mitotic chromosomes containing hyperacetylated histones. Histones were
extracted from the following: Lane 1, interphase nuclei isolated from butyrate-treated cells;
lane 2, interphase nuclei isolated from untreated cells; lane 3, metaphase chromosomes isolated
from untreated cells (note the shift in position of histone H1 due to its phosphorylation at
mitosis); lanes 4 and 5, two separate preparations of metaphase chromosomes isolated from
cells treated with butyrate starting in mid-S-phase and continuing until they arrested in mitosis
(as in Fig. 3, lane 5); lane 6, a mixture of the samples shown in lanes 1 and 3, to give
approximately the same ratio of H1M to H1I (and therefore the same amount of interphase
contamination) as seen in lanes 4 and 5. Acid-extracted histones were analyzed by acid-urea
polyacrylamide gel electrophoresis. Only the portion of the gel containing the histones is
shown.
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Fig. 6.
Acetylation of histones in crude lysates of HeLa cells. Lanes 1 – 7: Interphase (I) or metaphase-
arrested (M) cells were lysed and incubated in HAT buffer as described in Materials and
Methods, with (+) or without (-) 10 mM butyrate, 1 mM acetyl coenzyme A and 1 mM
cantharidin. Histones were extracted and analyzed on acid-urea gels. Lanes 8 – 9: Histones
extracted from interphase cells treated in vivo with (+) or without (-) 10 mM butyrate. Only
the portions of the gels containing the histones are shown.
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Fig. 7.
Assay of histone deacetylase activity in lysates of interphase and metaphase-arrested HeLa
cells. The assay is based on release of 3H from exogenous acid-extracted histones that were
labeled in vivo with [3H]-acetate (see Materials and Methods). (A) A lysate of 2.0 H 107 cells/
mL was tested for deacetylase activity over a time course of 9 mins. The release of 3H is linear
over time. (B) Various concentrations of lysate, up to 2.0 H 107 cells/mL, were tested for
deacetylase activity at one time point (5 min). The amount of [3H]-acetate released is
proportional to the lysate concentration. (C), (D) Comparison of HDAC activity in lysates (of
equivalent concentration) of (C) interphase and (D) metaphase-arrested HeLa cells. 10 separate
deacetylase assays were run using interphase lysates and 8 using metaphase-arrested lysates.
Error bars indicating two standard deviations from the mean are shown for each time point.
Note that the deacetylase activity is virtually identical for metaphase ( — ) and interphase ( — )
lysates. (E), (F) Effects of protein phosphatase inhibitors and butyrate on deacetylase activity
in HeLa lysates: (E) interphase lysates; (F) metaphase lysates. Cells were lysed either without
added inhibitors ( — ), with 50 mM sodium butyrate (∼—∼) to inhibit HDACs, or with protein
phosphatase inhibitors: 1 μM microcystin-LR ( — ) and 100 nM calyculin A ( — ).
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